<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011660</url>
  </required_header>
  <id_info>
    <org_study_id>115</org_study_id>
    <nct_id>NCT01011660</nct_id>
  </id_info>
  <brief_title>Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients</brief_title>
  <acronym>CHIEF</acronym>
  <official_title>Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the optimized treatment strategy of hypertension, so
      as to make more patients to reach the blood pressure goals and to reduce
      cardio-cerebrovascular events. Objective and Methods: Patients are eligible for inclusion in
      the study if they are essential hypertension, 50-79 years of age with at least one
      cardiovascular risk factor and sign the informed consent forms. This project is a
      multi-centre, prospective randomized,，openlabel blind-endpoint evaluation controlled (PROBE)
      trial. 12000 patients will be randomly assigned to either of low-dose Amlodipine+Telmisartan
      group or Amlodipine+ diuretics group. Among those patients with serum cholesterol between
      4.0-6.1mmol/L, they will be also randomized into small dose of statin-based regimen or
      standard management regimen; Patients will also randomly assigned to intensive lifestyle
      intervention group or standard intervention group according to the community area where the
      patients in.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to observe the main outcome (stroke, myocardial infarction and death from
      cardiovascular disease) differences between different groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary study outcomes are composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death.</measure>
    <time_frame>3-4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cardiovascular events；all-cause death, hospitalization for angina pectoris, coronary revascularization, aortic dissection, cerebrovascular disease, heart failure, renal insufficiency, tumor, new onset of atrial fibrillation and diabetes mellitus</measure>
    <time_frame>3-4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">13542</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>A,1,IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,2,IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A means active; 2 means Amlodipine+Telmisartan; IV means phase IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,3,IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,4,IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine, Telmisartan, Amiloride Compound , Simvastatin</intervention_name>
    <description>Amlodipine; Telmisartan; Amiloride Compound; Simvastatin</description>
    <arm_group_label>A,1,IV</arm_group_label>
    <arm_group_label>A,2,IV</arm_group_label>
    <arm_group_label>A,3,IV</arm_group_label>
    <arm_group_label>A,4,IV</arm_group_label>
    <other_name>CHIEF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  essential hypertension

          -  50-79 years old

          -  with at least one of the cardiovascular risk factor

          -  sign consent forms

        Exclusion Criteria:

          -  secondary hypertension

          -  attack of cerebrovascular events or myocardial infarction within recent 3 months

          -  coexistence of severe cardiomyopathy, rheumatic or congenital heart diseases

          -  unstable angina

          -  severe hepatopathy or nephropathy (ALT elevation &gt; 2 fold or serum creatinine &gt;
             2.5mg/dl)

          -  malignant tumor

          -  gout

          -  women taking contraceptives or with pregnancy

          -  allergic history to the research drugs

          -  validated contradiction to the research drugs

          -  participating in other clinical trials

          -  unable for long-term follow-up or poor compliance

          -  unsuitable for clinical trial at the discretion of doctors in charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wang Wen</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyuan Ma</last_name>
      <phone>86 10 68335002</phone>
      <email>maliyuan600@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Wen Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Ma Liyuan</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>drugs intervention</keyword>
  <keyword>lipid-lowering therapy</keyword>
  <keyword>50-79 years of age</keyword>
  <keyword>sign</keyword>
  <keyword>the informed</keyword>
  <keyword>consent</keyword>
  <keyword>forms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Amiloride</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

